Somewhat Positive Press Coverage Somewhat Unlikely to Impact Novavax (NVAX) Share Price
News articles about Novavax (NASDAQ:NVAX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novavax earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.7680361163299 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Analyst’s Proposition on Symantec Corporation (SYMC), Novavax, Inc. (NVAX) – AppsforPCdaily (appsforpcdaily.com)
- Novavax, Inc. (NVAX) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Novavax, Inc. (NVAX) Stock Price stands 7.03% away from 20 SMA – Voice Of Analysts (analystsbuzz.com)
- Novavax: Catalysts Building Toward A Crescendo – Novavax, Inc … – Seeking Alpha (seekingalpha.com)
Several research firms have recently commented on NVAX. Zacks Investment Research lowered Novavax from a “buy” rating to a “hold” rating in a research report on Saturday, August 19th. BidaskClub raised Novavax from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Ladenburg Thalmann Financial Services raised Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price target for the company in a research report on Wednesday, August 9th. Chardan Capital reissued a “neutral” rating and issued a $1.50 price target on shares of Novavax in a research report on Thursday, July 27th. Finally, Piper Jaffray Companies reissued a “hold” rating and issued a $1.50 price target on shares of Novavax in a research report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $3.05.
Shares of Novavax (NASDAQ NVAX) traded down 1.75% on Monday, reaching $1.12. The company had a trading volume of 4,543,640 shares. The firm’s 50 day moving average is $1.05 and its 200 day moving average is $1.10. The firm’s market capitalization is $324.69 million. Novavax has a 12 month low of $0.73 and a 12 month high of $2.47.
Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.16). Novavax had a negative return on equity of 787.38% and a negative net margin of 1,006.00%. The company had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $6.15 million. During the same period last year, the firm earned ($0.29) earnings per share. Novavax’s quarterly revenue was up 168.0% on a year-over-year basis. On average, equities research analysts expect that Novavax will post ($0.62) earnings per share for the current fiscal year.
In other Novavax news, Director James F. Young sold 175,000 shares of the firm’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total value of $185,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.00% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Novavax (NVAX) Share Price” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/09/18/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-novavax-nvax-share-price.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.